J&J buying Alios for $1.75B
Johnson & Johnson (NYSE:JNJ) is acquiring Alios BioPharma Inc. (South San Francisco, Calif.) for $1.75 billion in cash. The pharma receives Alios' antiviral assets, including AL-8176 to treat respiratory syncytial virus (RSV).
Pfizer, Kyowa partner on cancer combo trial
Pfizer Inc. (NYSE:PFE) and Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) will co-fund a Phase Ib trial of Pfizer's PF-05082566 plus Kyowa's Poteligeo mogamulizumab to treat solid tumors. Pfizer will run the U.S. trial, which is expected to start next year.
MacroGenics, Takeda announce second DART deal
MacroGenics Inc. (NASDAQ:MGNX) granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) an option to license exclusive, worldwide rights to four programs against undisclosed jointly selected targets. The products will be developed using MacroGenics' Dual-Affinity Re-Targeting (DART) technology.
Ebola plays up after Texas diagnosis
Post-market traders bid up prices of Ebola plays after the CDC and the Texas Department of State Health Services said a patient in a Texas hospital has been diagnosed with the infection. The agencies said the diagnosis is the first in the U.S.
Stem cell play ReproCell creates VC fund
ReproCell Inc. (JASDAQ:4978) and Shinsei Bank, a subsidiary of Shinsei Corporate Investment Ltd., raised Y800 million ($7.28 million) for Cell Innovation Partners LP.
POLITICS & POLICY
FDA starts clock on LDT regulation
On Tuesday, FDA released two draft guidance documents that outline the agency's plans for regulating laboratory-developed tests (LDTs). The draft guidance is largely in line with documents pre-released in July (see BioCentury, August 11).
CMS says payments database is "first wave"
CMS released what it called its "first wave" of its Open Payments database, which details consulting fees, research grants, travel reimbursements, and "other" gifts healthcare companies provided to physicians and teaching hospitals during the last five months of 2013.
NIAID funds development of new vaccine adjuvants
NIH's National Institute of Allergy and Infectious Diseases awarded five-year contracts to seven research institutions developing new vaccine adjuvants that boost responses by activating the adaptive immune system. The agency said total funding for all seven contracts could reach $70 million.
NIH awards $46M in BRAIN initiative grants
NIH issued $46 million in grants to support 58 research projects that are part of the Brain Research through Application of Innovative Neurotechnologies (BRAIN) initiative. Most of the grants are for new neuroscience tools and techniques, such as using lasers to guide nerve cell firing and stimulating circuits with radio waves.